Stock Track | Soleno Therapeutics Plummets 5.07% Amid Disappointing Q4 Earnings Miss

Stock Track

Mar 05, 2025

Soleno Therapeutics Inc. (SLNO) witnessed a sharp plummet of 5.07% in its stock price on Tuesday's intraday trading session. This significant drop followed the biotechnology company's release of its Q4 2024 earnings results, which missed analysts' expectations.

According to the earnings summary, Soleno Therapeutics reported a quarterly adjusted loss of $1.27 per share for the quarter ended December 31, 2024, wider than the analysts' consensus estimate of a $1.15 loss per share. The company also reported a substantial quarterly loss of $55.98 million, further exacerbating investors' concerns.

While Soleno Therapeutics did not provide any revenue, as expected by analysts, the company's shares had risen by 1.9% this quarter. However, the disappointing earnings results and the lack of positive catalysts appear to have triggered the steep sell-off in the stock, underscoring the market's sensitivity to the company's financial performance and prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1197912591"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197912591\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197912591?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 00:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197912591","market":"us","top_or_hot":-1,"title":"Stock Track | Soleno Therapeutics Plummets 5.07% Amid Disappointing Q4 Earnings Miss","media":"Stock Track","content":"<p>Soleno Therapeutics Inc. (SLNO) witnessed a sharp plummet of 5.07% in its stock price on Tuesday's intraday trading session. This significant drop followed the biotechnology company's release of its Q4 2024 earnings results, which missed analysts' expectations.</p>\n\n<p>According to the earnings summary, Soleno Therapeutics reported a quarterly adjusted loss of $1.27 per share for the quarter ended December 31, 2024, wider than the analysts' consensus estimate of a $1.15 loss per share. The company also reported a substantial quarterly loss of $55.98 million, further exacerbating investors' concerns.</p>\n\n<p>While Soleno Therapeutics did not provide any revenue, as expected by analysts, the company's shares had risen by 1.9% this quarter. However, the disappointing earnings results and the lack of positive catalysts appear to have triggered the steep sell-off in the stock, underscoring the market's sensitivity to the company's financial performance and prospects.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Soleno Therapeutics Plummets 5.07% Amid Disappointing Q4 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Soleno Therapeutics Plummets 5.07% Amid Disappointing Q4 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-05 00:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Soleno Therapeutics Inc. (SLNO) witnessed a sharp plummet of 5.07% in its stock price on Tuesday's intraday trading session. This significant drop followed the biotechnology company's release of its Q4 2024 earnings results, which missed analysts' expectations.</p>\n\n<p>According to the earnings summary, Soleno Therapeutics reported a quarterly adjusted loss of $1.27 per share for the quarter ended December 31, 2024, wider than the analysts' consensus estimate of a $1.15 loss per share. The company also reported a substantial quarterly loss of $55.98 million, further exacerbating investors' concerns.</p>\n\n<p>While Soleno Therapeutics did not provide any revenue, as expected by analysts, the company's shares had risen by 1.9% this quarter. However, the disappointing earnings results and the lack of positive catalysts appear to have triggered the steep sell-off in the stock, underscoring the market's sensitivity to the company's financial performance and prospects.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLNO","symbol_name":"Soleno Therapeutics","start_time":0,"source_url":"","article_id":"1197912591","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197912591","pubTimestamp":1741105377,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Soleno Therapeutics Inc.  witnessed a sharp plummet of 5.07% in its stock price on Tuesday's intraday trading session. This significant drop followed the biotechnology company's release of its Q4 2024 earnings results, which missed analysts' expectations.According to the earnings summary, Soleno Therapeutics reported a quarterly adjusted loss of $1.27 per share for the quarter ended December 31, 2024, wider than the analysts' consensus estimate of a $1.15 loss per share. The company also reporte","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLNO":"Soleno Therapeutics"},"translate_title":"由于第四季度盈利令人失望，Soleno Therapeutics股价暴跌5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":1},"content_text":"Soleno Therapeutics Inc. (SLNO) witnessed a sharp plummet of 5.07% in its stock price on Tuesday's intraday trading session. This significant drop followed the biotechnology company's release of its Q4 2024 earnings results, which missed analysts' expectations.\nAccording to the earnings summary, Soleno Therapeutics reported a quarterly adjusted loss of $1.27 per share for the quarter ended December 31, 2024, wider than the analysts' consensus estimate of a $1.15 loss per share. The company also reported a substantial quarterly loss of $55.98 million, further exacerbating investors' concerns.\nWhile Soleno Therapeutics did not provide any revenue, as expected by analysts, the company's shares had risen by 1.9% this quarter. However, the disappointing earnings results and the lack of positive catalysts appear to have triggered the steep sell-off in the stock, underscoring the market's sensitivity to the company's financial performance and prospects.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}